CClinicalTrials.gg
CompletedNCT06530680Updated Jul 31, 2024

Upper Extremity Function Before and After Hippotherapy in Children With Autism Spectrum Disorder and/or Cerebral Palsy

An interventional study of Hippotherapy in Autism Spectrum Disorder and Cerebral Palsy, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Ohio State University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Jun 2021, registered Jul 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The goal of this feasibility trial is to learn if hippotherapy and physical therapy in the equine environment can be used to improve upper extremity function in children with cerebral palsy or autism spectrum disorder who present with motor delay or impairment in the upper extremities. The main questions it aims to answer are:

Can the upper extremity-focused treatment using hippotherapy and the equine environment be delivered to fidelity?

Is the treatment acceptable to participants and therapists?

Is the randomized-controlled trial protocol feasible to scale to a larger study, including recruitment and retention rates and suitability of selected outcome measures?

If there is a comparison group: Researchers will compare participants receiving treatment to a waitlist control to see if participants are retained in the control group and if differences are detected between the control and treatment groups on selected outcome measures.

Read the detailed description

Intervention. Participants will receive 4 weeks of hippotherapy, 4 × 1-hour sessions per week, for a total of 16 hours of intervention. If the participants miss a session, make-up sessions will be offered, scheduled, and tracked.51

Hippotherapy: The hippotherapy intervention will be delivered at Dreams on Horseback in central Ohio using Professional Association of Therapeutic Horsemanship (PATH) Intl. standards. Participants will be mounted on a horse for at least 30 minutes of the 1-hour session. Activities for the remaining time include grooming and tacking of the horses, mounting, and dismounting. A herd of 9 horses will be used for hippotherapy sessions. There will be 2 volunteers assisting with every session: one to lead the horse, and one to walk alongside the participant opposite the treating therapist. Dreams on Horseback has a part-time Volunteer Coordinator who currently schedules 154 volunteers for 22 hours of equine-assisted activities per week (Monday - Saturday). Activities will include various positions on the horse such as sitting and quadruped (weight bearing through the upper extremities and knees), as well as reaching and throwing, controlling the horse with the reins, and riding the horse at a walk and a trot as is suggested by PATH Intl. Standards. Using the observation protocol in the preliminary data section, one researcher will video record one hippotherapy session each week and document the therapeutic activities performed. A second researcher will score 20% of the sessions to assure reliability of >90%. Categories expected based on preliminary data are transitions, ground poles, directional changes, reaches outside of base of support, reaches, weight bearing through upper extremities, using reins, holding upper extremities off of the horse, position on the horse (with or without stirrups, standing, sitting, posting), and kicking/squeezing the horse with legs. This analysis will allow the investigators to quantify the dose of hippotherapy, focus on the impact of therapeutic targets to the upper extremities, and allow the investigators to evaluate adherence to the hippotherapy protocol.

Treating Therapists: All treating therapists will be licensed PTs and will have completed at least the AHA Level I Hippotherapy Treatment Principles.

Since the goal of pilot studies is not to test efficacy, no inferential statistics are proposed. The investigators will analyze questions pertaining to 1) the recruitment success of children with CP+ASD ages 5-15; 2) whether participants adhere to what they are asked to do during the pilot RCT; and 3) if the treatment can be successfully delivered per protocol. The investigators will describe the number of potential participants screened per month; the number enrolled per month; the average time delay from screening to enrollment; and the average time to enroll enough participants for 2 groups. Treatment-specific retention and attrition rates for hippotherapy, including the reasons for dropouts, and treatment-specific fidelity rates, including a measure of dose of hippotherapy and upper extremity activities, will be described.

02

Conditions studied

03

In context

Cerebral Palsy

1,853 studies on the registry are indexed under Cerebral Palsy; 433 are open to participants now.

This study's enrollment of 12 is below the median of 33 across 1,368 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Ohio State University is the lead sponsor of 640 studies on the registry; 144 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 45 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children age 6 to 17
  • Diagnosis of Cerebral Palsy with Gross Motor Functional Classification System (GMFCS) Level I, II, or III with upper extremity affected Cerebral Palsy and/or Autism Spectrum Disorder
  • Able to follow simple verbal instructions in English
  • Able to tolerate sitting on a horse continuously for 30 minutes

Exclusion criteria

Exclusion Criteria:

  • Fear of or aversion to horses
  • Weight over 200 lb
  • Lacking independent head control (GMFCS level IV and V)
  • Both parents unable to speak and read English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Physical therapy incorporating hippotherapy and the equine environment

    Four 1 hour Hippotherapy treatments per week for four weeks.

    Behavioral: Hippotherapy

  • No intervention
    Waitlist Control

    A waitlist control that will receive hippotherapy intervention (four 1 hour Hippotherapy treatments per week for four weeks.) Four weeks later than the 'Physical therapy incorporating hippotherapy and the equine environment' Group.

Interventions

  • BehavioralHippotherapy

    Two 1-hour sessions of hippotherapy for eight weeks.

06

What researchers measure

Primary outcomes

  1. Reach-and grasp protocol

    Reach-and-grasp protocol: Participants were recorded while performing a reach-to-drink task. For each trial, participants were instructed: "Reach for the bottle, pick it up, pretend to take a drink, return the bottle to the marked position on the table, and return your hand to the start position. Do this twice." Movement of the upper extremities was recorded from reflective markers on the hands, wrists, elbows, shoulders, and sternum by a 10-camera VICON Motion Capture system at 120 Hz and filtered at 4 Hz with a low-pass Butterworth filter.

    Time frame: 1 week pre- and post- 4-week waitlist control period and within 1 week pre- and post- 4-week treatment period.

  2. PEM-CY

    Participation and Environment Measure for Children and Youth; higher scores mean better; participation scores range 0-7, involvement scores range 1-5.

    Time frame: 1 week pre- and post- 4-week waitlist control period and within 1 week pre- and post- 4-week treatment period

  3. PRIME-O

    Pediatric Rehabilitation Intervention Measure of Engagement - Observation; higher scores = more engaged; score range = 0-40 (0-4 per item)

    Time frame: 1 time per week during the 4-week intervention period

  4. PRIME-SP

    Pediatric Rehabilitation Intervention Measure of Engagement - Service Provider; not scaled

    Time frame: 1 time per week during the 4-week intervention period

  5. Enjoy

    Self-report measure of enjoyment of an activity. The scale has 25 statements that respondents rate on a 7-point Likert scale the degree to which they agree or disagree with each statement. There are 5 sections of the measure that cover different components of enjoyment: pleasure, relatedness, competence, challenge/improvement, and engagement. higher scores = more enjoyment; scores range 1-7 per item.

    Time frame: 1 time per week during the 4-week intervention period

  6. VABS

    Vineland Adaptive Behavior Scale 2nd Edition; high scores mean better; Adaptive Behavior Composite standard score range: 20-160.

    Time frame: 1 week pre- and post- 4-week waitlist control period and within 1 week pre- and post- 4-week treatment period

  7. CAPE/PAC

    Child Assessment of Participation and Enjoyment / Preference for Activities in Children; higher scores mean better; score range CAPE = 55-275 (1-5 per item), PAC = 55-165 (1-3 per item)

    Time frame: 1 week pre- and post- 4-week waitlist control period and within 1 week pre- and post- 4-week treatment period

07

Study locations

1 site
  • The Ohio State University
    Columbus, Ohio 43210, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06530680
Lead sponsor
Ohio State University
Collaborators
Nationwide Children's Hospital, University of Montana
Responsible party
Jill Heathcock (Professor, Ohio State University) — Principal investigator
First posted
Jul 31, 2024
Start date
Jun 14, 2021
Primary completion
Feb 3, 2023
Completion
Feb 3, 2023
Last update
Jul 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion